SELECTED REFERENCES: Pediatric Donor Management
1. Nakagawa TA, Mou SS. The Process of Organ Donation and Donor Management.
Furhman Textbook of Critical Care Medicine 4th Edition. 2011. Elsevier Mosby.
Philadelphia, PA
2. Nelson KL, Berkowitz ID. Organ Donation. In: Nichols DG, Ackerman AD,
Carcillo JA, Dalton JH, Kissoon N. Editors. Rogers’ Textbook of Pediatric
Intensive Care 4th Edition. Lippincott Williams and Wilkins.
3. Nakagawa TA, Mou SS. Management of the Pediatric Organ Donor. In: Rudow
D, Ohler L, Shafer T. Editors. The Clinician’s Guide to Donation and
Transplantation. North American Transplant Coordinators Organization NATCO.
Lenexa, KS: Applied Measurement Professionals Inc; 2006. Chapter 13;1-18.
4. Lutz-Dettinger N, de Jaeger A, Kerremans I. Care of the potential pediatric organ
donor. Pediatr Clin North Am 2001;48:715-749.
5. Novitzky D. Donor management: state of the art. Transplant Proc 1997;29:37733775.
6. Mallory GB, Schecter MG, Elidemir O. Management of the pediatric organ
donor to optimize lung donation. Pediatr Pulmonol. 2009;44:536-546.
7. Scheinkestel CD, Tuxen DV, Cooper DJ, Butt W. Medical management of the
(potential) organ donor. Anaesth Intensive Care 1995;23:51-59.
8. Wood KE, Becker BN, McCartney JG, et al. Care of the potential organ donor. N
Engl J Med 2004;351:2730-2739.
9. O'Connor KJ, Wood KE, Lord K. Intensive Management of Organ Donors to
Maximize Transplantation. Crit Care Nurse 2006;26:94-100.
10. Salim A, Martin M, Brown C, et al. Complications of Brain Death: Frequency and
Impact on Organ Retrieval. The American Surgeon 2006;72:377-380.
11. Mascia L, Bosma K, Pasero D, et al.. Ventilatory and hemodynamic management
of potential organ donors: An observational survey. Crit Care Med 2006;34:321327.
12. Angel LF, Levine DJ, Restrepo MI, et al. Impact of a lung-transplantation donormanagement protocol on lung donation and recipient outcomes. Am J Resp Crit
Care Med 2006;174:710-716.
Pediatric Donor Management/References/Nakagawa 2012
13. Straznicka M, Follette DM, Eisner MD, et al. Aggressive management of lung
donors classified as unacceptable: excellent recipient survival one year after
transplantation. J Thorac Cardiovasc Surg 2002;124:250-258.
14. Rosengard BR, Feng S, Alfrey EJ, et al. Report of the Crystal City meeting to
maximize the use of organs recovered from the cadaver donor. Am J Transplant
2002;2:701-711.
15. Venkateswaran RV, Patchell VB, Wilson IC, et al. Early donor management
increases the retrieval rate of lungs for transplantation. Ann Thorac Surg.
2008;85(1):278-86.)
16. McElhinney DB, Khan JH, Babcock WD, Hall TS. Thoracic organ donor
characteristics associated with successful lung procurement. Clin Transplant
2001;15:68-71.
17. Cooper DKC, Novitsky D, Wicomb WN. The pathophysiological effects of brain
death on potential donor organs, with particular reference to the heart. Ann R Coll
Surg Engl 1989;71:261-266.
18. Lopez-Aguilar J, Villagra A, Bernabe F, et al. Massive brain injury enhances lung
damage in an isolated lung model of ventilatory-induced lung injury. Crit Care
Med 2005;33:1077-1083.
19. Salim A, Martin M, Brown C, Belzberg H, Rhee P, Demetriades D.
Complications of Brain Death: Frequency and Impact on Organ Retrieval. The
American Surgeon 2006;72:377-380.
20. Grossman MD, Reilly PM, McMahon DJ. Loss of potential organ donors due to
medical failure. Crit Care Med 1996;24:A76.
21. Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic
donor management results in more transplanted organs. Transplantation
2003;75:482-487.
22. Salim A, Velmahos GC, Brown C. et al. Aggressive organ donor management
significantly increases the number of organs available for transplantation. J
Trauma. 2005;58:991-994.
23. Salim A, Martin M, Brown C. et al. The effect of a protocol of aggressive donor
management: Implications for the national organ donor shortage. J Trauma.
2006;61:429-435.
24. Schnuelle P, Gorrmann U, Hoegar S, et al Effects of donor pretreatment with
dopamine on graft function after kidney transplantation: a randomized controlled
trial. JAMA 2009;302:1067-1075.
Pediatric Donor Management/References/Nakagawa 2012
25. Power BM, Van Heerden PV. The physiological changes associated with brain
death--current concepts and implications for treatment of the brain dead organ
donor. Anaesth Intensive Care 1995;23:26-36.
26. Razek T, Olthoff K, Reilly PM. Issues in potential organ management. Surg Clin
North Am. 2000;80:1021-32.
27. Amado JA, Lopez-Espada F, Vazquea-Barquero A, et al. Blood levels of
cytokines in brain-dead patients: relationships with circulating hormones and
acute-phase reactants. Metabolism 1995;44:812-816.
28. Lopez SP, Hernandez JO, Moreno NV, et al. Brain death effects on catecholamine
levels and subsequent cardiac damage assessed in organ donors. J Heart Lung
Transplant 2009;28:815-820.
29. Schnuelle P, Berger S, deBoer J, et al. Effects of catecholamine application to
brain-dead donors on graft survival in solid organ transplantation.
Transplantation 2001;72:455-463.
30. Barron ME, Wilkes MM, Navickis RJ. A systematic review of the comparative
safety of colloids. Arch Surg 2004;139:552-563.
31. Cittanova ML, Leblanc I, Legendre C, et al. Effect of hydroxyethylstarch in braindead kidney donors on renal function in kidney-transplant recipients. Lancet
1996;348:1620-1622.
HORMONAL RESUSCITATION THERAPY
32. Macdonald PS, Aneman A, Ghonadgiri D, et al. A systematic review and metaanalysis of clinical trials of thyroid hormone administration to brain dead
potential organ donors. Crit Care Med 2012;40: 1635-1644.
33. Salim A, Martin M, Brown C. et al. Using thyroid hormone in brain-dead donors
to maximize the number of organs available for transplantation. Clin Transplant
2007;21:405-409
34. Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields
more transplanted hearts with improved early function. Transplantation 2003.
27;75(8):1336-41.
35. Novitzky D, Cooper DK, Morrell D, Isaacs S. Change from aerobic to anaerobic
metabolism after brain death, and reversal following triiodothyronine therapy.
Transplantation 1988;45:32-36.
Pediatric Donor Management/References/Nakagawa 2012
36. Taniguchi S, Kitamura S, Kawachi K, et al. Effects of hormonal supplements on
the maintenance of cardiac function in potential donor patients after cerebral
death. Eur J Cardiothorac Surg 1992;6:96-102.
37. Venkateswaran RB, Steeds RP, Quinn DW, et al. The haemodynamic effects of
adjunctive hormone therapy in potential heard donors: a prospective randomized
double-blind factorially designed controlled trial. Eur Heart J 2009;30:1771-80.
38. Venkateswaran RV, Dronavalli V, Lamber PA, et al. The proinflammatory
environment in potential heart and lung donors: prevalence and impact of donor
management and hormonal therapy. Transplantation 2009;88:582-588.
39. Salim A, Vassiliu P, Velmahos GC, et al. The role of thyroid hormone
administration in potential organ donors. Arch Surg 2001;136:1377-1380.
40. Zuppa AF, Nadkarni V, Davis L, et al. The effect of a thyroid hormone infusion
on vasopressor support in critically ill children with cessation of neurologic
function. Crit Care Med 2004;32:2318-2322.
41. Katz K, Lawler J, Wax J, et al. Vasopressin pressor effects in critically ill children
during evaluation for brain death and organ recovery. Resuscitation 2000;47:3340.
42. Finfer S, Bohn D, Colpitts D, et al. Intensive care management of paediatric organ
donors and its effect on post-transplant organ function. Intensive Care Med
1996;22:1424-1432.
43. Cherick WS, Edwards LB, Sweet SC, et al. The effect of hormonal resuscitation
on organ utilization in pediatric donors. Abstract. Presented at the Pediatric
Summit for Organ Donation and Transplantation. San Antonio, Texas. 2007.
44. Orlowski JP, Spees EK. Improved cardiac transplant survival with thyroxine
treatment of hemodynamically unstable donors: 95.2% graft survival at 6 and 30
months. Transplant Proc 1993;25:1535.
45. Cooper DK, Novitzky D, Wicomb WN, et al. A review of studies relating to
thyroid hormone therapy in brain-dead organ donors. Front Biosci. 2009;14:375070.
46. Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and the heart.
Circulation 1993;87:1435-1441.
47. Ririe DG, Butterworth JF IV, Royster RL, et al. Triiodothyronine increases
contractility independent of beta-adrenergic receptors or stimulation of cyclic3',5'-adenosine monophosphate. Anesthesiology 1995;82:1004-1012.
Pediatric Donor Management/References/Nakagawa 2012
48. Goarin JP, Cohen S, Riou B, et al. The effects of triiodothyronine on
hemodynamic status and cardiac function in potential heart donors. Anesth Analg
1996;83:41-47.
49. Marik PE, Zaloga GP. Adrenal insufficiency in the critically ill: a new look at an
old problem. Chest 2002;122:1784-1796.
50. Ullian ME. The role of corticosteriods in the regulation of vascular tone.
Cardiovasc Res 1999;41:55-64.
51. Dimopoulou I, Tsagarakis S, Anthi A, Milou E, et al. High prevalence of
decreased cortisol resesrve in brain-dead potential organ donors. Crit Care Med
2003;31:1113-1117.
52. Follette DM, Rudich SM, Babcock WD. Improved oxygenation and increased
lung donor recovery with high-dose steroid administration after brain death. J
Heart Lung Transplant 1998;17:423-429.
53. DePerrot M, Snell GI, Babcock WD, et al. Strategies to optimize the use of
currently available lung donors. J Heart Lung Transpl 2004;23:1127-1134.
54. Totsuka E, Fung U, Hakamada K, et al. Analysis of clinical variables of donors
and recipients with respect to short-term graft outcome in human liver
transplantation. Transplant Proc 2004;36:2215-2218.
55. Takemoto CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook, 12th ed.
Hudson, OH: Lexi-Comp. 2005:1287-1288.
56. Lugo N Silver P, Nimkoff L, Caronia C, Sagy M. Diagnosis and management
algorithm of acute onset of central diabetes insipidus in critically ill children. J
Pediatr Endocrinology and Metab 1997;10:633-639.
57. Pennefather SH, Bullock RE, Mantle D, Dark JH. Use of low dose arginine
vasopressin to support brain-dead organ donors. Transplantation 1995;59:58-62.
58. Agerso H, Seiding Larsen L, Riis A, Lovgren U, et al. Pharmacokinetics and renal
excretion of desmopressin after intravenous administration to healthy subjects and
renally impaired patients. Br J Clin Pharmacol 2004;58:352-358.
59. Kohler M, Harris A. Pharmacokinetics and haematological effects of
desmopressin. Eur J Clin Pharmacol 1988;35:281-285.
Pediatric Donor Management/References/Nakagawa 2012